Apogee Therapeutics, Inc. (APGE)
Every FINRA and SEC series the site collects for Apogee Therapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
4.3M
Short interest
settlement 2026-08-14
3.2
Days to cover
+1.3% vs prior
41.7%
Short share of volume
2026-09-02
26
Fails to deliver
settlement 2026-08-11
-$17.5M
Insider flow, 90 days
0 buys, 4 sells
As of 2026-09-08.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in APGE is 4,273,438 shares, up 140,142 shares over the last month. Over the last 48 readings it ranged from 4,133,296 shares (15 July 2026) to 10,526,394 shares (29 May 2026). The latest reading sits at the bottom of that range. At the reported average volume of 1.3M shares a day that is 3.2 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/apge" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 4,273,438 | +1.3% | 1,324,883 | 3.23 |
| 2026-07-31 | 4,217,209 | +2.0% | 1,047,072 | 4.03 |
| 2026-07-15 | 4,133,296 | -19.9% | 1,740,933 | 2.37 |
| 2026-06-30 | 5,161,455 | -50.7% | 10,062,043 | 1.00 |
| 2026-06-15 | 10,477,522 | -0.5% | 1,016,327 | 10.31 |
| 2026-05-29 | 10,526,394 | +12.3% | 1,124,634 | 9.36 |
| 2026-05-15 | 9,371,143 | -1.3% | 591,084 | 15.85 |
| 2026-04-30 | 9,489,537 | -0.8% | 663,969 | 14.29 |
| 2026-04-15 | 9,567,729 | -1.7% | 616,265 | 15.53 |
| 2026-03-31 | 9,729,380 | +10.6% | 1,603,880 | 6.07 |
| 2026-03-13 | 8,798,347 | +2.1% | 882,938 | 9.96 |
| 2026-02-27 | 8,619,325 | -0.9% | 610,700 | 14.11 |
| 2026-02-13 | 8,700,530 | -2.4% | 959,948 | 9.06 |
| 2026-01-30 | 8,913,346 | +10.1% | 1,203,004 | 7.41 |
| 2026-01-15 | 8,093,742 | -6.6% | 1,038,933 | 7.79 |
| 2025-12-31 | 8,664,816 | +2.3% | 960,179 | 9.02 |
| 2025-12-15 | 8,472,837 | +7.3% | 958,132 | 8.84 |
| 2025-11-28 | 7,898,663 | -0.4% | 608,396 | 12.98 |
| 2025-11-14 | 7,931,680 | -0.3% | 798,505 | 9.93 |
| 2025-10-31 | 7,954,445 | -6.9% | 708,706 | 11.22 |
| 2025-10-15 | 8,545,761 | -9.6% | 1,074,878 | 7.95 |
| 2025-09-30 | 9,448,327 | +5.6% | 550,373 | 17.17 |
| 2025-09-15 | 8,947,262 | -2.8% | 568,077 | 15.75 |
| 2025-08-29 | 9,201,255 | +0.8% | 400,535 | 22.97 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 2 September 2026, the short share of APGE volume is 41.7%, up 26.7 points over the last five sessions. Over the last 52 readings it ranged from 6.3% (30 June 2026) to 65.8% (21 July 2026). The latest reading is 12.6 points above the 30-session average of 29.1%, on 341K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-02 | 142K | 341K | 41.7% | 1,800 |
| 2026-09-01 | 58K | 579K | 10.0% | 1 |
| 2026-08-31 | 69K | 216K | 31.9% | 88 |
| 2026-08-28 | 53K | 115K | 46.5% | 0 |
| 2026-08-27 | 44K | 250K | 17.5% | 0 |
| 2026-08-26 | 106K | 708K | 15.0% | 0 |
| 2026-08-25 | 49K | 156K | 31.6% | 1 |
| 2026-08-24 | 244K | 398K | 61.4% | 0 |
| 2026-08-21 | 91K | 402K | 22.7% | 9,378 |
| 2026-08-20 | 102K | 603K | 16.9% | 155 |
| 2026-08-19 | 58K | 607K | 9.5% | 0 |
| 2026-08-18 | 82K | 373K | 22.1% | 0 |
| 2026-08-17 | 105K | 390K | 26.9% | 8,140 |
| 2026-08-14 | 406K | 772K | 52.6% | 1,524 |
| 2026-08-13 | 95K | 323K | 29.5% | 2,011 |
| 2026-08-12 | 63K | 282K | 22.3% | 2 |
| 2026-08-11 | 205K | 558K | 36.8% | 1 |
| 2026-08-10 | 57K | 212K | 26.7% | 17 |
| 2026-08-07 | 95K | 676K | 14.0% | 1,019 |
| 2026-08-06 | 76K | 408K | 18.5% | 2 |
| 2026-08-05 | 82K | 1.0M | 8.2% | 6,914 |
| 2026-08-04 | 466K | 1.5M | 30.2% | 2,000 |
| 2026-08-03 | 93K | 300K | 31.0% | 0 |
| 2026-07-31 | 108K | 812K | 13.3% | 18 |
| 2026-07-30 | 64K | 258K | 24.7% | 0 |
| 2026-07-29 | 96K | 324K | 29.4% | 385 |
| 2026-07-28 | 85K | 305K | 28.0% | 429 |
| 2026-07-27 | 79K | 160K | 49.3% | 5,010 |
| 2026-07-24 | 49K | 82K | 60.3% | 0 |
| 2026-07-23 | 77K | 174K | 44.1% | 1,117 |
Fails to deliver
SEC, by settlement date. JSONAs of 11 August 2026, the fails-to-deliver balance in APGE is 26 shares, up 18 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (5 August 2026) to 333,212 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-11 | 26 | $134.65 | $4K |
| 2026-08-10 | 8 | $134.84 | $1K |
| 2026-08-07 | 28 | $134.49 | $4K |
| 2026-08-05 | 1 | $134.19 | $134 |
| 2026-08-04 | 3 | $134.11 | $402 |
| 2026-07-30 | 3,718 | $134.20 | $499K |
| 2026-07-29 | 17 | $134.17 | $2K |
| 2026-07-20 | 8,230 | $134.00 | $1.1M |
| 2026-07-17 | 32 | $134.08 | $4K |
| 2026-07-06 | 581 | $132.91 | $77K |
| 2026-07-02 | 1,245 | $132.77 | $165K |
| 2026-07-01 | 8 | $132.73 | $1K |
| 2026-06-30 | 1,496 | $132.61 | $198K |
| 2026-06-29 | 333,212 | $132.55 | $44.2M |
| 2026-06-24 | 32,232 | $132.88 | $4.3M |
| 2026-06-22 | 52,475 | $90.38 | $4.7M |
| 2026-06-18 | 49,990 | $88.43 | $4.4M |
| 2026-06-16 | 96 | $86.19 | $8K |
| 2026-06-08 | 26,344 | $86.92 | $2.3M |
| 2026-06-05 | 100 | $90.90 | $9K |
| 2026-06-03 | 375 | $78.71 | $30K |
| 2026-04-30 | 10,332 | $82.03 | $848K |
| 2026-04-21 | 2,373 | $90.92 | $216K |
| 2026-04-20 | 6,094 | $92.20 | $562K |
| 2026-04-17 | 59,996 | $90.55 | $5.4M |
| 2026-04-16 | 6 | $89.32 | $536 |
| 2026-04-15 | 251 | $88.47 | $22K |
| 2026-04-13 | 29,965 | $86.27 | $2.6M |
| 2026-04-07 | 75 | $84.01 | $6K |
| 2026-03-30 | 6 | $77.82 | $467 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at APGE reported 4 open-market sells worth $17.5M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Shah Nimish P on 2026-09-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Shah Nimish P | n/a | Disposition | 1.8M | $135.11 | $236.4M | 0 |
| 2026-09-02 | Dambkowski Carl | Chief Medical Officer | Disposition | 1K | $135.06 | $186K | 167K |
| 2026-08-07 | Fairmount Funds Management LLC | n/a | Option exercise | 10K | $43.85 | $455K | 341K |
| 2026-08-07 | Fairmount Funds Management LLC | n/a | Option exercise | 32K | $17.00 | $541K | 330K |
| 2026-08-05 | Dambkowski Carl | Chief Medical Officer | Sell | 6K | $134.17 | $738K | 168K |
| 2026-08-05 | Dambkowski Carl | Chief Medical Officer | Option exercise | 4K | $22.86 | $94K | 174K |
| 2026-07-24 | Henderson Jane | Chief Financial Officer | Gift | 15K | $0.00 | $0 | 158K |
| 2026-07-14 | Dambkowski Carl | Chief Medical Officer | Gift | 8K | $0.00 | $0 | 170K |
| 2026-07-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Gift | 75K | $0.00 | $0 | 921K |
| 2026-07-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 20K | $133.63 | $2.7M | 996K |
| 2026-06-22 | Dambkowski Carl | Chief Medical Officer | Sell | 26K | $132.60 | $3.5M | 179K |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 80K | $132.54 | $10.6M | 1.0M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 614 | $86.89 | $53K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $86.27 | $199K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $85.19 | $134K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 1K | $84.18 | $91K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $82.78 | $634K | 1.1M |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 7K | $82.21 | $557K | 1.1M |
| 2026-06-03 | Dambkowski Carl | Chief Medical Officer | Sell | 6K | $78.71 | $433K | 206K |
| 2026-06-03 | Dambkowski Carl | Chief Medical Officer | Option exercise | 4K | $22.86 | $94K | 211K |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 1K | $82.58 | $111K | 1.1M |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 19K | $82.05 | $1.5M | 1.1M |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Sell | 2K | $84.60 | $152K | 207K |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Sell | 4K | $83.92 | $311K | 209K |
| 2026-05-06 | Dambkowski Carl | Chief Medical Officer | Option exercise | 4K | $22.86 | $94K | 213K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 289 | $83.16 | $24K | 173K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 900 | $82.60 | $74K | 174K |
| 2026-05-01 | Henderson Jane | Chief Financial Officer | Sell | 811 | $81.02 | $66K | 175K |
| 2026-04-16 | Henderson Jane | Chief Financial Officer | Sell | 2K | $90.00 | $180K | 175K |
| 2026-04-16 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Option exercise | 3K | $22.86 | $69K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 200 | $85.00 | $17K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 2K | $83.26 | $167K | 1.1M |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 18K | $82.48 | $1.5M | 1.1M |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 100 | $85.89 | $9K | 208K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $85.33 | $231K | 208K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $84.31 | $227K | 211K |
| 2026-04-01 | Dambkowski Carl | Chief Medical Officer | Option exercise | 4K | $22.86 | $94K | 214K |
| 2026-04-01 | Henderson Jane | Chief Financial Officer | Sell | 1K | $85.46 | $94K | 177K |
| 2026-04-01 | Henderson Jane | Chief Financial Officer | Sell | 900 | $84.46 | $76K | 178K |
| 2026-03-25 | Henderson Jane | Chief Financial Officer | Sell | 2K | $85.00 | $170K | 179K |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 3K | $75.86 | $259K | 1.2M |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $74.83 | $615K | 1.2M |
| 2026-03-11 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | Sell | 8K | $74.29 | $621K | 1.2M |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 200 | $73.26 | $15K | 210K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 2K | $71.98 | $149K | 210K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Sell | 3K | $70.33 | $227K | 212K |
| 2026-03-04 | Dambkowski Carl | Chief Medical Officer | Option exercise | 4K | $22.86 | $94K | 215K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 406 | $71.66 | $29K | 181K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 994 | $70.45 | $70K | 182K |
| 2026-03-02 | Henderson Jane | Chief Financial Officer | Sell | 300 | $68.27 | $20K | 183K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON11 holders above 5% have filed on APGE, 11 on Schedule 13D (active intent). The largest reported stake is Nimish Shah at 0.0% of the class (0 shares), filed 2026-09-08 for an event on 2026-09-03.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-08 | 13D/Ano. 1 | Nimish Shahindividual | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Venrock Healthcare Capital Partners EG, L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | VHCP Management III, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | VHCP Management EG, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Bong Y. Kohindividual | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | Venrock Healthcare Capital Partners III, L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-08 | 13D/Ano. 1 | VHCP Co-Investment Holdings III, LLCother entity | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Fairmount Healthcare Fund II L.P.partnership | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Peter Evan Harwinindividual, parent holding company | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Tomas Kiselakindividual, parent holding company | 0 | 0.0% | 2026-09-03 |
| 2026-09-03 | 13D/Ano. 7 | Fairmount Funds Management LLCinvestment adviser | 0 | 0.0% | 2026-09-03 |
13F holders
Tracked managers holding APGE at their latest 13F. JSON8 of the 30 tracked managers held APGE at their latest 13F, $355.1M in total at quarter-end prices. Millennium Management is the largest at $199.3M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.5M | $199.3M | 0.07% | new or n/a |
| Soros Fund Management | 2026-06-30 | 565K | $74.9M | 0.92% | new or n/a |
| D. E. Shaw & Co. | 2026-06-30 | 246K | $32.7M | 0.02% | +187K |
| Renaissance Technologies | 2026-06-30 | 147K | $19.5M | 0.03% | +106K |
| Two Sigma Investments | 2026-06-30 | 95K | $12.6M | 0.01% | -187K |
| Citadel Advisors | 2026-06-30 | 59K | $7.8M | 0.00% | -594K |
| Point72 Asset Management | 2026-06-30 | 55K | $7.2M | 0.01% | +41K |
| AQR Capital Management | 2026-06-30 | 8K | $1.1M | 0.00% | -69 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Apogee Therapeutics, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Apogee Therapeutics, Inc. (APGE), SEC CIK 1974640, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-09-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1974640Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of APGE is sold short?
What is APGE's daily short volume?
Does APGE have fails to deliver?
Are APGE insiders buying or selling?
Who owns more than 5% of APGE?
Which funds hold APGE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.